Replies to post #10343 on Innovus Pharmaceuticals Inc. (fka INNV)

[TrueTrades]

$2.5m in revenues is high range this q
$4m in operating expenses is likely
justify that please
its been 5 quarters of exponential negative earnings growth while the whole time the co touts its revenue growth
you figure it out
i call it a scam
oh and no fluti
no fluti
as far as apri it has been a looser since before damaje
i did make $ there on that jan pop
but i digresss
we are long past discussing the details

[Biotech Pharmer]

Jtaylor, as far as Damaj's tenure at APRI, I compared the stock price when he started to the stock price when he left, accounting for the 2010 reverse split. My figures illustrating that the stock was down 45% during his tenure is spot on. Get over it. What's your excuse for INNV being down 75% since he started here? You just keep putting more lipstick on that pig.